Is OnKure Therapeutics, Inc. (OKUR) overvalued? · P/E 72, $76.6M cap
OnKure Therapeutics, Inc. (OKUR) is a biotechnology company listed on US.
This page asks whether OnKure Therapeutics, Inc. (OKUR) looks expensive on cached numbers — not a short thesis.
Latest reported OKUR revenue for 2024-12-31 was $0. Net income was -$52.7M. OKUR currently screens at market cap $76.6M and trailing P/E 71.8.
OKUR currently screens at market cap $76.6M and trailing P/E 71.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OKUR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OKUR stock page for the full model, not this heading.
Not investment advice.